View Older Stories View More Recent Stories

Feb 28, 2017 04:01PM Biogen to Present at the Cowen & Company 37th Annual Health Care Conference
Feb 15, 2017 05:29PM Biogen to Present at the 2017 RBC Capital Markets Global Healthcare Conference
Feb 14, 2017 03:11PM Eaton Park's 13F Shows New Stakes in Bank of America (BAC), Comcast (CMCSA), Comerica (CMA) (More...)
Feb 7, 2017 04:01PM Biogen to Present at the Leerink Partners 6th Annual Global Healthcare Conference
Feb 1, 2017 07:33AM Biogen (BIIB) Completes Separation of Bioverativ (BIVV)
Feb 1, 2017 07:30AM Biogen Completes Separation of Global Hemophilia Business, Bioverativ
Jan 26, 2017 06:30AM Biogen Reports 2016 Revenues of $11.4 Billion
Jan 17, 2017 04:01PM Biogen Fourth Quarter and Year End 2016 Financial Results Webcast Adjusted to 8:00 am on January 26, 2017
Jan 17, 2017 10:30AM Siemens Healthineers and Biogen Announce Agreement to Jointly Develop New MRI Tools for Multiple Sclerosis
Jan 17, 2017 09:29AM Pre-Open Stock Movers 01/17: (FWP) (CLSN) (GEVO) Higher; (ADHD) (CBK) (UEC) Lower (more...)
Jan 17, 2017 07:31AM Biogen (BIIB), Forward Pharma (FWP) Enter Settlement and License Agreement; Biogen to Pay $1.25B, Royalties
Jan 17, 2017 07:30AM Biogen and Forward Pharma Agree to Enter into Settlement and License Agreement
Jan 13, 2017 07:33AM Biogen (BIIB) Phase 3 Data on SPINRAZA Shows Significantly Reduced Risk of Death in SMA
Jan 13, 2017 07:30AM New Data Show SPINRAZA™ (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation in Infantile-Onset Spinal Muscular Atrophy
Jan 12, 2017 08:00AM Biogen Spin-off Bioverativ Commences When-Issued Trading of Common Stock
Dec 27, 2016 05:45AM Biogen (BIIB) Receives FDA Approval for SPINRAZA to Treat SMA (IONS)
Dec 23, 2016 05:08PM U.S. FDA Approves Biogen’s SPINRAZA™ (nusinersen), The First Treatment for Spinal Muscular Atrophy
Dec 23, 2016 04:51PM U.S. FDA Approves Biogen’s SPINRAZA™ (nusinersen), The First Treatment for Spinal Muscular Atrophy
Dec 22, 2016 04:39PM Biogen (BIIB) Form 10 for Bioverativ Spin Declared Effective
Dec 22, 2016 04:36PM Biogen Announces Effectiveness of Bioverativ Form 10 Registration Statement
Dec 22, 2016 08:00AM Biogen Announces that Bioverativ will Host an Investor Day on January 6, 2017
Dec 21, 2016 04:01PM Biogen and Spin-off Bioverativ will Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
Dec 21, 2016 08:00AM Biogen to Report Fourth Quarter and Year End 2016 Financial Results on January 26, 2017
Dec 20, 2016 04:02PM Biogen (BIIB) Approves Separation of Bioverativ (BIVV); Declares Special Dividend
Dec 20, 2016 04:01PM Biogen’s Board of Directors Approves Separation of Bioverativ and Declares Special Dividend Distribution of Bioverativ Stock
Dec 20, 2016 09:00AM Biogen to Present at the 35th Annual J.P. Morgan Healthcare Conference
Dec 19, 2016 04:20PM Biogen (BIIB) Names Michel Vounatsos CEO
Dec 19, 2016 04:20PM Biogen Names Michel Vounatsos Chief Executive Officer
Dec 8, 2016 06:16PM Biogen Presents Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab at 2016 Clinical Trials on Alzheimer’s Disease Meeting
Dec 5, 2016 07:04AM Biogen (BIIB), Sobi Announce Presentation of ELOCTATE, ALPROLIX Data at ASH 2016
Dec 3, 2016 07:00AM Data Reinforcing the Long-Term Safety and Efficacy of Extended Half-Life Hemophilia Therapies ELOCTATE® and ALPROLIX® Highlighted at 58th ASH Meeting
Nov 23, 2016 09:24AM Pre-Open Stock Movers 11/23: (MDGS) (VEEV) (BLXT) Higher; (JUNO) (LLY) (URBN) Lower (more...)
Nov 15, 2016 07:49AM Biogen (BIIB) Names Two New Executives for Bioverativ Spinoff
Nov 15, 2016 07:30AM Biogen Announces Additional Members of Management Team of Hemophilia Spin-off Company Bioverativ
Nov 14, 2016 02:00PM Eton Park Capital's 13F Shows New Stakes Twitter (TWTR), Kinder Morgan (KMI), Whitewave (WWAV), Increase in Microsoft (MSFT) (More...)
Nov 7, 2016 07:32AM Biogen (BIIB), Ionis Pharma (IONS) Announce SPINRAZA Phase 3 Met Primary Endpoint in Later-Onset SMA
Nov 7, 2016 07:30AM Biogen and Ionis Pharmaceuticals Announce SPINRAZA (nusinersen) Meets Primary Endpoint at Interim Analysis of Phase 3 CHERISH Study in Later-Onset Spinal Muscular Atrophy
Oct 28, 2016 07:38AM Biogen (BIIB) Announces U.S. FDA, EMA Acceptance of Nusinersen Regulatory Applications
Oct 28, 2016 07:30AM Biogen’s Regulatory Applications for Nusinersen as a Treatment for Spinal Muscular Atrophy Accepted by FDA and EMA
Oct 27, 2016 04:01PM Biogen to Present at the 25th Annual Credit Suisse Healthcare Conference
Oct 26, 2016 09:15AM Pre-Open Stock Movers 10/26: (OGXI) (AKAM) (IRBT) Higher; (EW) (NUVA) (P) (CMG) (AAPL) Lower (more...)
Oct 26, 2016 06:59AM Biogen Reports Record Third Quarter 2016 Revenues of $3.0 Billion
Oct 8, 2016 10:00AM New Data Presented at World Muscle Society Congress Support Potential Benefit of Investigational Treatment Nusinersen in Spinal Muscular Atrophy
Sep 28, 2016 09:10AM Pre-Open Stock Movers 09/28: (SEED) (AVXL) (ATHX) Higher; (GALT) (TPX) (SONC) Lower (more...)
Sep 28, 2016 07:02AM Biogen (BIIB) to Test Anavex Life Sciences (AVXL) Lead Drug Candidate ANAVEX 2-73
Sep 28, 2016 07:00AM Anavex Compound to be Tested in Biogen Neurological Protection Model
Sep 26, 2016 07:52AM Biogen (BIIB), Ionis (IONS) Announce Completion of Nusinersen NDA Rolling Submission as SMA Treatment
Sep 26, 2016 07:30AM Biogen Completes Rolling Submission of New Drug Application to FDA for Nusinersen as a Treatment for Spinal Muscular Atrophy
Sep 15, 2016 07:33AM Biogen (BIIB), AbbVie (ABBV) Announce Significant ZINBRYTA Data in NEDA vs AVONEX
Sep 15, 2016 07:30AM New Data Presented at ECTRIMS Reinforce Efficacy of ZINBRYTA™ (Daclizumab) and Support Long-Term Safety Profile
View More Recent Stories View Older Stories